Study to Evaluate the Efficacy and Safety of Tezepelumab in Reducing Oral Corticosteroid Use in Adults With Oral Corticosteroid Dependent Asthma

PHASE3CompletedINTERVENTIONAL
Enrollment

150

Participants

Timeline

Start Date

March 5, 2018

Primary Completion Date

September 25, 2020

Study Completion Date

September 25, 2020

Conditions
Asthma
Interventions
BIOLOGICAL

Tezepelumab

Tezepelumab subcutaneous injection

OTHER

Placebo

Placebo subcutaneous injection

Trial Locations (60)

1646

Research Site, San Fernando

4300

Research Site, Lutsk

5500

Research Site, Mendoza

10367

Research Site, Berlin

10461

Research Site, The Bronx

10717

Research Site, Berlin

10969

Research Site, Berlin

15120

Research Site, Homestead

16059

Research Site, Bursa

16602

Research Site, Altoona

19140

Research Site, Philadelphia

19713

Research Site, Newark

21029

Research Site, Vinnytsia

22299

Research Site, Hamburg

23552

Research Site, Lübeck

27705

Research Site, Durham

27834

Research Site, Greenville

29406

Research Site, North Charleston

29621

Research Site, Anderson

30625

Research Site, Hanover

34098

Research Site, Istanbul

34741

Research Site, Kissimmee

34746

Research Site, Kissimmee

42415

Research Site, Daegu

43617

Research Site, Toledo

44130

Research Site, Cleveland

45030

Research Site, Manisa

45231

Research Site, Cincinnati

48109

Research Site, Ann Arbor

49007

Research Site, Dnipro

55131

Research Site, Mainz Am Rhein

56068

Research Site, Koblenz

63141

Research Site, St Louis

63739

Research Site, Aschaffenburg

73000

Research Site, Kherson

73109

Research Site, Oklahoma City

75069

Research Site, McKinney

78251

Research Site, San Antonio

81377

Research Site, München

93301

Research Site, Bakersfield

96049

Research Site, Bamberg

02721

Research Site, Fall River

C1414AIF

Research Site, Buenos Aires

C1425BEN

Research Site, Ciudad de Buenos Aire

X5003DCE

Research Site, Córdoba

B1878FNR

Research Site, Quilmes

T4000IAR

Research Site, San Miguel de Tucumán

D-30173

Research Site, Hanover

31-559

Research Site, Krakow

90-153

Research Site, Lodz

53-301

Research Site, Wroclaw

03082

Research Site, Seoul

03312

Research Site, Seoul

03722

Research Site, Seoul

05505

Research Site, Seoul

06351

Research Site, Seoul

06591

Research Site, Seoul

01330

Research Site, Adana

06230

Research Site, Ankara

06280

Research Site, Ankara

Sponsors

Lead Sponsor

Collaborators (1)

All Listed Sponsors
collaborator

Amgen

INDUSTRY

lead

AstraZeneca

INDUSTRY